Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brachytherapy for clinically localized prostate cancer.

H Ragde1, L Korb

  • 1Urology, Northwest Prostate Institute, Northwest Hospital, Seattle, Washington 98133, USA.

Seminars in Surgical Oncology
|January 5, 2000
PubMed
Summary

Prostate brachytherapy using Iodine-125 offers effective long-term cancer control for localized prostate cancer. This treatment shows comparable or superior outcomes to surgery and external beam radiation, with excellent disease-free survival rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.

Archivos espanoles de urologia·2001
Same author

Modern prostate brachytherapy.

CA: a cancer journal for clinicians·2001
Same author

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.

Cancer·2000
Same author

Radiotherapy for the palliation of prostate cancer.

Seminars in surgical oncology·2000
Same author

Follow-up evaluation of a phase II prostate cancer vaccine trial.

The Prostate·1999
Same author

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.

The Prostate·1999

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Prostate brachytherapy is a recognized treatment for localized prostate carcinoma.
  • Long-term follow-up data demonstrates its efficacy compared to other treatment modalities.
  • Established techniques and outcomes are crucial for patient and physician guidance.

Purpose of the Study:

  • To evaluate the long-term outcomes of Iodine-125 prostate brachytherapy.
  • To compare brachytherapy results with radical prostatectomy and external-beam radiation therapy.
  • To present up-to-date implant techniques and historical review of the procedure.

Main Methods:

  • A cohort of 152 patients with Stage T1-T3 prostate cancer received Iodine-125 brachytherapy between 1987 and 1988.
  • Patients had a median age of 70 years and varying Gleason grades.

Related Experiment Videos

  • Disease-free survival was assessed at 5 and 10 years post-treatment via PSA levels, clinical exams, and biopsies.

    • Main Results:

    • 5- and 10-year follow-up showed prostate-specific antigen (PSA) levels comparable to radical prostatectomy series.
    • Brachytherapy outcomes were superior to several published external-beam radiation series.
    • Treatment failure was defined by PSA elevation (>0.5 ng/ml), positive biopsy, or positive bone scan.

    Conclusions:

    • Iodine-125 prostate brachytherapy is an effective treatment for organ-confined prostate cancer.
    • Long-term results support brachytherapy's role in managing localized prostate carcinoma.
    • The study highlights the importance of ongoing follow-up and advanced implant techniques.